N11102014
Press Releases
More Ascletis News
Copyright © 2011-2015 Ascletis Inc. All rights reserved.
News & Events

ascletis

   Home

Nov 10, 2014   Ascletis gains exclusive China market rights from Presidio to  clinical stage hepatitis C virus (HCV) NS5A inhibitor PPI-668  >>

N11102014

Mar 18, 2015   Ascletis’s HCV drug ASC08 Phase 2 data presented at annual Asian-Pacific Association for the Study of Liver  >>

N03182015

Mar 19, 2015   Special report of Ascletis’  ASC08 by  Zhejiang Daily  on China’s Protect Liver Day  >>

Mar 23, 2015   BioWorld Today - Ascletis’ triple theray HCV drug nails phase II trial in Chinese patients  >>

Oct 28, 2014   Ascletis to build commercial cGMP facility in Shaoxing Binhai New City  >>

N10282014 20150319ZhejiangDailyCh.pdf BioWorld20150323.pdf

News & Events

Investor Center

Careers

Pipeline

Partnership

About  Us

About Us

Research & Development

Research & Development Pipeline Partership Investor Center News & Events Careers
Home

中文

Contact
Contact    Home    Home-Ch 浙ICP备11050387号

Think Outside the Box

CCTV Report on HCV
Partnership
APASL Panel Review
Partership

Ascletis is a specialty therapeutics company dedicated to discovering

and developing important new treatments for cancer and infectious diseases.

APASL2015Prof.Wei.pdf

Status and Treatment Trends of HCV

HCV IN CHINA

HCV

Danoprevir

HIV in China